Editor’s Note: Michael pushed this out to his free Strategic Tech Investor readers last night. Now that they’ve had the chance to get ready, we want to make sure everyone has a chance to cash in here. To get Michael’s free tech and pot stock investing research for yourself each week, just click here. Here he is…
I knew legal cannabis began to step out of the shadows and onto the big stage when some of its largest and best-run firms started listing on major U.S. stock exchanges.
Two Canadian companies have done that so far – uplisting their OTC-traded stocks to one of the big American exchanges.
At the end of February, Cronos Group Inc. (Nasdaq: CRON) uplisted to the Nasdaq, while Canopy Growth Corp. (NYSE: CGC) debuted on the New York Stock Exchange on May 19.
Both of those were big news at the time.
And for a very good reason, as I’ll show you...
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Legal Weed Is Hitting In the Big Leagues Now
Quite simply, these young, aggressive, and above all well-positioned firms are now on the same playing field as some of the top tech names in the world.
That hasn’t escaped the attention of Wall Street.
Drop Everything: Canada just became the first major economy to legalize marijuana nationwide, giving investors a once-in-a-lifetime chance to potentially make millions of dollars from Canadian marijuana companies. Learn more…
You see, fund managers who run $1 billion-plus portfolios are often hamstrung by strict limits on what they can own.
Often, for example, they can only hold stocks that are traded on major exchanges. In other words, fund managers and other big spenders who like these companies now have the green light to buy. We're talking about pension funds, mutual funds, hedge funds, and more.
That's a lot of potential buying pressure from institutional investors that should keep interest alive – and money rolling in.
But, for all that, we still haven't seen a cannabis initial public offering (IPO) on one of the big U.S. exchanges.
Until now...
Pot’s Potential Makes This One of Few IPOs Worth Following
A British Columbia-based cannabis startup – one I've been watching for years now – just began marketing its upcoming Nasdaq IPO.
A “roadshow” unlike any other is in the offing.
That means its executives and marketing team have signed up their banking partners... and are hitting the road in order to show (and, of course, sell) its IPO to big-money investors.
It values its IPO at near $1.5 billion – and will make its debut on the Nasdaq Global Select Market exchange.
"In general, U.S. capital markets have generally been closed to growers. [This company] is reflecting that exchanges like Nasdaq and New York [Stock Exchange] are starting to open up to the fact that cannabis is a legitimate marketplace," Scott Greiper, president and founder of cannabis-focused investment bank Viridian Capital Advisors, said. "Every exchange is looking to be on the front lines of capital markets."
And that trend is only going to escalate as more U.S. states – and more nations around the world – continue to legalize cannabis.
This seed-to-sale cannabis company has a long history of being a "first mover" in its sector. Not only is it the first marijuana company to IPO on a major U.S. exchange, but it was the first Canadian cannabis company to distribute its marijuana at home and internationally.
That gives it entry into not only the $4.7 billion Canadian market, but the international market as well. That market is expected to reach $57 billion by 2027, according to Arcview Market Research – and some analysts believe it could reach $1 trillion in short order.
When this company makes its debut, it’ll complete the perfect “Big Weed” triple-play, along with Cronos and Canopy Growth – two pot stocks I recommend accumulating here.
Canada’s Cannabis Billions Could Be Unleashed, Potentially Overnight
Now, I've already laid out my case for this soon-to-be public Canadian company in a special report that's free to select members of my Radical Technology Profits service. You can click here to learn how to get it.
I told those subscribers that it's the "Canadian cannabis IPO I'm watching closest right now" – and that was before the Nasdaq news broke.
But the truth is, weed investing is about more – much more – than a promising IPO.
Just to give you an idea of the potential here, by 2027, it's expected that about 40% of all legal marijuana across the globe will be sold in Canada. All told, Canada's total legal weed market – when you add in the growers, the value-added product makers, the testing labs, security, tourism, exports, and all the rest – could soon reach $22.6 billion, according to Deloitte.
Those incredible statistics cannot be understated.
And they're why I believe investors should be focusing their attention on Canada-based marijuana companies and stocks, like Cronos and Canopy Growth.
I've got more details on how to get in on the future $22.6 billion industry – and that historic IPO – before they take off... Check it all out by clicking here.
Follow Money Morning on Facebook, Twitter, and LinkedIn.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.